Evidence map›Paper›PMID 42285993›Full record

ArticleNature communications2026

Surpassing homochiral assemblies in chiroptical activity through enantiomeric imbalance.

Xin Wen, Runjia Wang, Li Zhang, Minghua Liu

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xin WenKey Laboratory of Colloid, Interface and Chemical Thermodynamics Institute of Chemistry, Chinese Academy of Sciences (CAS), Beijing, China.
Runjia WangKey Laboratory of Colloid, Interface and Chemical Thermodynamics Institute of Chemistry, Chinese Academy of Sciences (CAS), Beijing, China.
Li ZhangKey Laboratory of Colloid, Interface and Chemical Thermodynamics Institute of Chemistry, Chinese Academy of Sciences (CAS), Beijing, China. zhangli@iccas.ac.cn.ORCID http://orcid.org/0000-0001-8525-4509
Minghua LiuKey Laboratory of Colloid, Interface and Chemical Thermodynamics Institute of Chemistry, Chinese Academy of Sciences (CAS), Beijing, China. liumh@iccas.ac.cn.ORCID http://orcid.org/0000-0002-6603-1251

Funding

National Natural Science Foundation of China (National Science Foundation of China) 52321006
6 · The paper itself

Abstract

Amplifying asymmetry via supramolecular self-assembly is essential for understanding homochirality in biology and developing functional chiroptical materials. While the "majority rules" dictates the handedness of heterochiral assemblies, their chiroptical signals are typically weaker than those of homochiral ones. Here, we demonstrate that controlled enantiomeric imbalance can enhance chiroptical activity beyond that of homochiral assemblies. Using dansyl-glutamic acid diamide enantiomers, we show that fine-tuning enantiomeric excess (ee) triggers structural reorganization, yielding maximum circular dichroism (CD) and circularly polarized luminescence (CPL) intensities exceeding those of pure enantiomer assemblies at specific ee values. Simulations reveal that the incorporation of the minority enantiomer constructively forms "chiral oligomers", which are composed of different ratios of enantiomers and optimize local chromophore alignment via effective pitch angle to amplify the chiroptical activity. This strategy overcomes the conventional signal attenuation from racemic or near-racemic mixing, enabling chiral imbalance-driven asymmetric amplification and offering a rational design principle for high-performance chiroptical materials.

Identifiers

PMID42285993
PMCPMC13407881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.